Searching map area
Simona Soverini
? TBD
researcher
Join to rate
Ratings
0
Nobody has rated this yet. Be the first!
Works
8
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
article by Simona Soverini et al published 15 December 2006 in Clinical Cancer Research
Targeted therapy and the T315I mutation in Philadelphia-positive leukemias
scientific article published on 01 April 2007
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia
scientific article published on 01 November 2006
Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia
article
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o
article by Simona Soverini et al published 20 June 2005 in Journal of Clinical Oncology
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib
scientific article published on 01 October 2011
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in t
scientific article published on 30 December 2013
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
scientific article published on 01 March 2007
Lists
0
Join to rate
Instance of
Human
Occupation
Researcher
Wikidata